SANOFI news, videos and press releases - Page 7
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
- Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia
- FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease
- FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
- European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)
- CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
- Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies
- EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
- Availability of the Q3 2020 Memorandum for modelling purposes
- Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
- Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
- Sanofi : Information concerning the total number of voting rights and shares - July 2020
- Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
- Sanofi to acquire Principia Biopharma
- Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
- Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial
- Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
- Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
- Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
- Sanofi: Information concerning the total number of voting rights and shares - May 2020
- Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors
- Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis
- Sanofi invests to make France its world class center of excellence in vaccine research and production
- Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan
- Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
- Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
- Sanofi announces closing of Regeneron stock sale
- Sanofi names new leaders to Executive Committee
- Sanofi announces pricing of Regeneron stock offering
- Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
